COPD Trial, Recruiting NCT07213128 Sponsor: KU Leuven Condition: COPD
Back to Copd

COPD Trial, Recruiting

NCT07213128
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been admitted to hospital for at least 3 days due to a sudden worsening of COPD symptoms
  • People who can read and speak French, Dutch, or English
  • People aged 35 years or older
  • People who are able to give their informed agreement to participate in the trial
  • People who own a smartphone that is compatible with a remote monitoring app and can use it to take part in video calls

Who may not be able to join:

  • People who are already doing inspiratory muscle training (a type of breathing exercise using a special device) at the time of joining the trial
  • People whose life expectancy is estimated to be less than 90 days
  • People whose main lung condition is something other than COPD
  • People who have an active cancer diagnosis
  • People who are unable to perform the breathing exercises or complete questionnaires, for example due to a neurological or cognitive condition
  • People who have an unstable heart rhythm problem or reduced blood flow to the heart that is currently active
  • People who currently have a collapsed lung
  • People who have a lung-reducing procedure planned within the next 180 days
  • People who are on a waiting list for a lung transplant
  • People who are admitted to a specialist in-hospital rehabilitation ward
  • People who are already taking part in another clinical trial related to COPD that could affect this trial's results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Daniel Langer, PhD, KU Leuven

Phone: 0032498606820

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
KU Leuven
Registry
ClinicalTrials.gov
Start date
6 January 2026
Est. completion
1 June 2028

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Composite outcome (all-cause hospital readmission or mortality)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov